IL-LENOVO
6.6.2024 15:01:32 CEST | Business Wire | Press release
Motorola and the Lenovo Foundation are committed to inclusion and smarter technology for all, and today we reaffirm this dedication with the expansion of our Indigenous Languages Support Initiative. As part of our ongoing efforts to raise awareness and empower Indigenous communities, Motorola is proud to announce the addition of Ladin, a minority language spoken in Italy’s Dolomites region (South of Tyrol), to the list of over 90 languages supported in our smartphones.
United Nations Educational, Scientific and Cultural Organization (UNESCO) estimates that one Indigenous language disappears every two weeks, resulting in the potential loss of around 3,000 unique languages by the end of the century. That’s why over the past three years, Motorola has been at the forefront of this mission, championing the revitalization of endangered languages across the globe.
With a focus on Europe for our latest phase of the Indigenous Languages Support Initiative, Motorola conducted extensive research to identify minority and endangered languages needing support. Among the languages considered, Ladin became a significant candidate, being one of the 12 officially recognized minority languages in Italy and one of three without a kinstate, or entity that is close to the region where their kin-groups reside. With only 30,000 speakers, UNESCO classifies Ladin as an endangered language.
"We've learned over the past few years that it is imperative that we work closely with the community of speakers and scholars that are passionate and committed to saving and promoting the language,” said Janine Oliveira, Executive Director of Software Globalization, Motorola. “This rang true for the Ladin community and made the decision to digitize the language in our devices easy."
Motorola worked alongside the Lenovo Foundation, and several translators and reviewers from the Ladin Institute, Micurá de Rü, led by Professor Paul Videsott, Professor for Romance Philology at the Free University of Bozen-Bolzano (UNIBZ). “This will definitely help Ladin and other minority languages to be more visible,” said Professor Videsott. “Smartphones are like the pencil of the 21st century, and having minority languages, including Ladin, in the motorola edge 50 series, has the same importance of having a language in a book.”
At Motorola, we know indigenous populations are interacting with mobile technology and are one of many diverse groups that make up our valued consumer base. It’s why we started the project, as we aim to preserve human heritage and the unique histories of Indigenous cultures while empowering future generations. But we also believe we have a responsibility to inspire others to do the same. Through June 2024, Motorola has open-sourced over 1 million translated indigenous words, allowing other companies to promote these languages through their interfaces, furthering revitalization efforts worldwide. Today, we’re also excited to share the latest version of our Hello Indigenous whitepaper written in partnership with Lenovo Foundation and UNESCO, serving as a blueprint for others to follow in their footsteps.
Ladin is the latest of several endangered languages that Motorola has added to its smartphone interface, including Kuvi and Kangri (spoken in regions of India), Cherokee (spoken in the United States), Kaingang (spoken in Brazil) and Nheengatu (spoken in the Amazon). Motorola remains committed to our mission of inclusion and cultural preservation, leveraging technology to bridge linguistic divides and foster a more diverse and interconnected world. To access the full data sets for each of our digitized endangered Indigenous languages, please visit: https://www.motorola.com/us/about/endangered-indigenous-languages-data-set.
Legal Disclaimers
Certain features, functionality and product specifications may be network dependent and subject to additional terms, conditions, and charges. All are subject to change without notice. MOTOROLA, the Stylized M Logo, MOTO and the MOTO family of marks are trademarks of Motorola Trademark Holdings, LLC. ©2024 Motorola Mobility LLC. All rights reserved.
About Motorola & Lenovo
Lenovo is a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub. Motorola Mobility LLC was acquired by Lenovo Group Holdings in 2014. Motorola Mobility is a wholly owned subsidiary of Lenovo, and is responsible for designing and manufacturing all Moto and Motorola branded mobile handsets and solutions. To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub and Motorola Global Blog.
About Lenovo Foundation
Lenovo Foundation is the charitable and philanthropic arm of Lenovo, a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606632567/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom